Literature DB >> 10732637

Considerations for the global assessment and treatment of patients with recalcitrant wounds.

S Seaman1.   

Abstract

Many factors, both intrinsic and extrinsic, may contribute to wound recalcitrance. For example, arterial circulation may be impaired by atherosclerosis, vasospastic disorders, microemboli, thromboangiitis obliterans, vasculitis, sickle cell anemia, and antiphospholipid syndrome, all of which may impair healing. Inflammatory disorders that may lead to recalcitrance include pyoderma gangrenosum and necrobiosis lipoidica. Chronic venous insufficiency, infection, diabetes mellitus, systemic malignancy, malnutrition, and exposure to pressure and shear prolong the healing process. Wounds secondary to primary skin carcinoma will not heal. Calciphylaxis, a life-threatening metabolic disorder, leads to multiple ulcerations that are especially difficult to heal. Knowledge of common factors that lead to wound recalcitrance is essential to the wound care clinician, as accurate diagnosis results in appropriate treatment. To arrive at the diagnosis, the wound care clinician must perform a thorough history and physical examination and order relevant investigative studies. Treatment is based on correction of the identified underlying condition. By utilizing a systematic approach in the management of each patient with a chronic wound, the wound care clinician increases the probability of achieving wound closure.

Entities:  

Mesh:

Year:  2000        PMID: 10732637

Source DB:  PubMed          Journal:  Ostomy Wound Manage        ISSN: 0889-5899            Impact factor:   2.629


  2 in total

1.  Prevalence of chronic wounds and structural quality indicators of chronic wound care in Dutch nursing homes.

Authors:  Armand A L M Rondas; Jos M G A Schols; Ellen E Stobberingh; Ruud J G Halfens
Journal:  Int Wound J       Date:  2013-10-24       Impact factor: 3.315

2.  Definition of infection in chronic wounds by Dutch nursing home physicians.

Authors:  A A L M Rondas; J M G A Schols; E E Stobberingh; P E Price
Journal:  Int Wound J       Date:  2009-08       Impact factor: 3.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.